Advances in Hematology / 2016 / Article / Tab 3 / Review Article
Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature Table 3 Transplant outcomes.
Reference Engraf. failure Med. days to neut./PLT eng. aGVHD II–IV/III-IV cGVHD NRM Relapse EFS/PFS OS O’Donnell et al., 2002 [24 ] 20% Cohort 2 15/14 46%/23% 1/10 limited 1/10 died of GVHD 4/10 cohort 2 relapsed At med. f/u 6 mo. 5/10 in CR At med. f/u 6 mo. 6/10 (cohort 2) alive Luznik et al., 2008 [25 ] 13% 15/24 34%/6% Ext. 5% in 2 doses of CY versus 25% in one dose of Cy 1 y 15% 1 y 51% 2 y EFS 26% 2 y 36% Symons et al., 2011 [26 ] 4% 25/32 14%/7.3% 13% 100 D 12% 1 y 66% poor risk 1 y 13% in CR 1 y 23.5% 1 y 40% Brunstein et al., 2011 [27 ] 2% 16/24 32%/0 1 y 13% 1 y 7% 1 y 45% 1 y PFS 48% 1 y 62% Pingali et al., 2014 [28 ] 4.7% 18/NA 32.6%/7.8% 21.3%/Ext. 10% 25% 3 y 30.1% 3 y PFS 42.3% 1 y OS 64% Median OS for 1st SCT 25.6 mo. 2nd SCT 6.5 mo. Solomon et al., 2012 [29 ] 0% 16/27 30%/10% 35%/severe 5% 1 y 10% 1 y 40% 1 y DFS 50% 1 y 69% Raiola et al., 2013 [30 ] 6% 18/23 12%/6% 26%/Ext. 0 6 mo. 18% 18 mo. 22% DFS 18 mo. 51% 18 mo. 62% Raj et al., 2014 [31 ] 4% 17/21 II 35% III 8% IV 0% 18% @ 2 y 2 severe cases 1 y 17% 2 y 28% 2 y 51% 2 y 48% Bhamidipati et al., 2014 [32 ] 6% 15/18 All grades 53%/17% 8% @ 2 y Ext. only in 1 patient 1 y 17% 1 y 38% 1 y 53% 1 y 62%
Castagna et al., 2014 [33 ] NA BM 21/29 25%/3% 13% 2 y 19% 1 y 22% 2 y PFS 62% 2 y 68% NA PB 20/27 33%/14% 13% 1 y 12% Solomon et al., 2015 [34 ] 0 16/25 43%/23% 56%/Ext. 10% 2 y 3% 2 y 24% 2 y DFS 73% 2 y 78%
Bradstock et al., 2015 [35 ] 0 15/18 I–III 55.1% No IV 28.6% 6 mo. 0 2 y 43.9% 2 y EFS 44.9% 2 y 52.7% 13% 16/24 I–III 48.5% No IV 32.3% 6 mo. 0 2 y 23.5% 2 y EFS 63.6% 2 y 83.4% Gayoso et al., 2013 [36 ] NA 18/27 33%/14% 24%/Ext. 12% 6 mo. 19% NA 1 y EFS 48% 1 y 60% Sugita et al., 2015 [37 ] 13% (0 in no h/o SCT; 31% in h/o SCT) 19/35 23%/3% 15%/none severe 1 y 23% 1 y 45% 1 y DFS 34% 1 y 45%
aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; CR, complete remission; Cy, cyclophosphamide; D, day; DFS, disease-free survival; Engraf., engraftment; EFS, event-free survival; Ext., extensive; mo., months; neut., neutrophils; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; PLT, platelets; y, year.